Drug General Information
Drug ID	D04YEW
Former ID	DIB005258
Drug Name	Tarafenacin
Synonyms	SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
Drug Type	Small molecular drug
Indication	Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81]		Phase 2	[523669]
Company	Laboratorios SALVAT SA
Structure		Download 2D MOL 3D MOL
Formula	C21H20F4N2O2
Canonical SMILES	C1N2CC[C@@H]([C@H]1OC(=O)N(c1cc(ccc1)F)Cc1cc(c(c(c1)F)F<br />)F)CC2
CAS Number	CAS 385367-47-5
PubChem Compound ID	25147683
Target and Pathway
Target(s)	Muscarinic acetylcholine receptor M3	Target Info	Antagonist	[529966]
KEGG Pathway	Calcium signaling pathway
	Neuroactive ligand-receptor interaction
	Cholinergic synapse
	Regulation of actin cytoskeleton
	Insulin secretion
	Salivary secretion
	Gastric acid secretion
	Pancreatic secretion
PANTHER Pathway	Alzheimer disease-amyloid secretase pathway
	Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
	Muscarinic acetylcholine receptor 1 and 3 signaling pathway
PathWhiz Pathway	Gastric Acid Production
Reactome	Muscarinic acetylcholine receptors
	Acetylcholine regulates insulin secretion
	G alpha (q) signalling events
WikiPathways	Monoamine GPCRs
	Calcium Regulation in the Cardiac Cell
	Regulation of Actin Cytoskeleton
	GPCRs, Class A Rhodopsin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
	GPCRs, Other
References
Ref 523669	ClinicalTrials.gov (NCT01458197) A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.. U.S. National Institutes of Health.
Ref 529966	In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.